Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | X4P-001 |
Synonyms | |
Therapy Description |
Mavorixafor (X4P-001), is a CXCR4 antagonist, which blocks the binding of CXCL12 to prevent metastasis and may activate cytotoxic T-lymphocytes (PMID: 23538388). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
X4P-001 | Mavorixafor|X4P-001-IO|AMD-070|AMD-11070|AMD11070 | CXCR4 Inhibitor 15 | Mavorixafor (X4P-001), is a CXCR4 antagonist, which blocks the binding of CXCL12 to prevent metastasis and may activate cytotoxic T-lymphocytes (PMID: 23538388). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02667886 | Phase Ib/II | Axitinib X4P-001 | Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma | Completed | USA | 1 |